blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1569638

EP1569638 - AMINOALKOXYINDOLES AS 5-HT6-RECEPTOR LIGANDS FOR THE TREATMENT OF CNS-DISORDERS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  11.07.2008
Database last updated on 24.04.2024
Most recent event   Tooltip18.09.2009Lapse of the patent in a contracting state
New state(s): TR		published on 21.10.2009  [2009/43]
Applicant(s)For all designated states
F. Hoffmann-La Roche AG
Grenzacherstrasse 127
4070 Basel / CH
[2005/36]
Inventor(s)01 / ZHAO, Shu-Hai
426 Ositos Avenue
Sunnyvale, CA 94086 / US
 [2005/36]
Representative(s)Braun, Axel
F.Hoffmann-La Roche AG
Patent Department (PLP)
124 Grenzacherstrasse
4070 Basel / CH
[N/P]
Former [2005/36]Braun, Axel
F.Hoffmann-La Roche AG Patent Department (PLP), 124 Grenzacherstrasse
4070 Basel / CH
Application number, filing date03782240.027.11.2003
[2005/36]
WO2003EP13372
Priority number, dateUS20020430506P03.12.2002         Original published format: US 430506 P
[2005/36]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2004050085
Date:17.06.2004
Language:EN
[2004/25]
Type: A1 Application with search report 
No.:EP1569638
Date:07.09.2005
Language:EN
The application published by WIPO in one of the EPO official languages on 17.06.2004 takes the place of the publication of the European patent application.
[2005/36]
Type: B1 Patent specification 
No.:EP1569638
Date:05.09.2007
Language:EN
[2007/36]
Search report(s)International search report - published on:EP17.06.2004
ClassificationIPC:A61K31/404, C07D209/30, C07D403/12, C07D401/12, C07D498/06, A61P25/28
[2005/36]
CPC:
C07D401/12 (EP,KR,US); C07D209/30 (EP,KR,US); A61K31/4025 (KR);
A61K31/404 (KR); A61K9/02 (KR); A61K9/20 (KR);
A61K9/48 (KR); A61P1/00 (EP); A61P1/14 (EP);
A61P25/00 (EP); A61P25/06 (EP); A61P25/08 (EP);
A61P25/14 (EP); A61P25/16 (EP); A61P25/18 (EP);
A61P25/24 (EP); A61P25/28 (EP); A61P25/30 (EP);
A61P25/32 (EP); A61P25/34 (EP); A61P25/36 (EP);
A61P3/04 (EP); A61P43/00 (EP); C07D403/12 (EP,KR,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   RO,   SE,   SI,   SK,   TR [2005/36]
Extension statesALNot yet paid
LT04.07.2005
LV04.07.2005
MKNot yet paid
TitleGerman:AMINOALKOXYINDOL-DERIVATE ALS 5-HT6-REZEPTORLIGANDEN ZUR BEKÄMPFUNG VON ZNS-KRANKHEITEN[2005/36]
English:AMINOALKOXYINDOLES AS 5-HT6-RECEPTOR LIGANDS FOR THE TREATMENT OF CNS-DISORDERS[2005/36]
French:INDOLS AMINOALKOXY UTILISES EN TANT QUE LIGANDS DU RECEPTEUR 5-HT6 POUR LE TRAITEMENT DE TROUBLES DU SNC[2005/36]
Entry into regional phase04.07.2005National basic fee paid 
04.07.2005Designation fee(s) paid 
04.07.2005Examination fee paid 
Examination procedure24.06.2004Request for preliminary examination filed
International Preliminary Examining Authority: EP
04.07.2005Examination requested  [2005/36]
07.11.2006Despatch of a communication from the examining division (Time limit: M04)
09.02.2007Reply to a communication from the examining division
12.03.2007Communication of intention to grant the patent
23.07.2007Fee for grant paid
23.07.2007Fee for publishing/printing paid
Opposition(s)06.06.2008No opposition filed within time limit [2008/33]
Fees paidRenewal fee
07.11.2005Renewal fee patent year 03
06.11.2006Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY05.09.2007
CZ05.09.2007
DK05.09.2007
EE05.09.2007
RO05.09.2007
SI05.09.2007
SK05.09.2007
TR05.09.2007
LU27.11.2007
MC30.11.2007
BG05.12.2007
GR06.12.2007
PT06.02.2008
[2009/43]
Former [2009/40]CY05.09.2007
CZ05.09.2007
DK05.09.2007
EE05.09.2007
RO05.09.2007
SI05.09.2007
SK05.09.2007
LU27.11.2007
MC30.11.2007
BG05.12.2007
GR06.12.2007
PT06.02.2008
Former [2009/35]CY05.09.2007
CZ05.09.2007
DK05.09.2007
EE05.09.2007
RO05.09.2007
SI05.09.2007
SK05.09.2007
MC30.11.2007
GR06.12.2007
PT06.02.2008
Former [2009/29]CZ05.09.2007
DK05.09.2007
EE05.09.2007
RO05.09.2007
SI05.09.2007
SK05.09.2007
MC30.11.2007
GR06.12.2007
PT06.02.2008
Former [2009/11]CZ05.09.2007
DK05.09.2007
EE05.09.2007
RO05.09.2007
SK05.09.2007
MC30.11.2007
GR06.12.2007
PT06.02.2008
Former [2008/35]CZ05.09.2007
DK05.09.2007
RO05.09.2007
SK05.09.2007
MC30.11.2007
GR06.12.2007
PT06.02.2008
Former [2008/29]CZ05.09.2007
RO05.09.2007
SK05.09.2007
MC30.11.2007
GR06.12.2007
PT06.02.2008
Former [2008/25]CZ05.09.2007
SK05.09.2007
GR06.12.2007
PT06.02.2008
Former [2008/22]GR06.12.2007
Cited inInternational search[A]WO9007505  (STERLING DRUG INC [US]) [A] 1-19* page 64, line 20 - page 65, line 19; example -; claim - *;
 [Y]WO9808817  (AMERICAN HOME PROD [US]) [Y] 1-19 * page 7, lines 9-15; example -; claim - * * page 19, line 1 - page 21, line 20 *;
 [A]WO0109142  (UPJOHN CO [US], et al) [A] 1-19 * page 18, line 30 - page 25, line 8; example -; claim - *;
 [Y]WO02059088  (WYETH CORP [US]) [Y] 1-19 * examples 4,8,10,20; claim - *;
 [Y]WO02085853  (WYETH CORP [US]) [Y] 1-19 * claims 1-11,22 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.